About this event
This IPOPI webinar will provide an introduction to the crossover between PIDs and SIDs.
The webinar is directed towards medical professionals with an interest in PID as well as patient group leaders and PID patients. The scope of the webinar will be clinically oriented, and suitable for a non-medical audience as well.
You can access the webinar through your browser or through a mobile devices. It will be recorded and can be accessed for streaming on IPOPI TV after the date.
Hosted by
-
Guest speaker
Dr Virgil Dalm DoctorG
Obtained his medical degree in 2005 and registered as internist-clinical immunologist in 2011. Since then he is working as internist-clinical immunologist in the Primary Immunodeficiency center at Erasmus MC, Rotterdam, the Netherlands. His clinical work focuses on care for adult patients with primary and secondary immunodeficiency disorders and transition care for adolescents with primary immunodeficiency disease. His goals are to improve early diagnosis, to individualize and to personalize patient care, in order to improve health outcome and quality of life in patients with rare PIDs.
-
Guest speaker
Silvia Sanchez-Ramon DoctorG
Associate Professor of Immunology, Complutense University of Madrid School of Medicine, since 2014. Consultant Clinical Immunologist at the Hospital Universitario Clínico San Carlos, since 2013. Consultant Immunologist at the Hospital General Universitario Gregorio Marañón, Madrid, Spain since 2001. President of the Immunology Society of the Community of Madrid.
-
Team member
Ipopi OfficeT
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is an international not for profit organisation dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency (PID) patients worldwide.
IPOPI
Improving PID patients' lives. Worldwide.The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is an international not for profit organisation dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency (PID) patients worldwide.
